Cytotherapy

Papers
(The TQCC of Cytotherapy is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial Board120
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.67
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY63
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC57
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION49
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA48
Aims and Scope46
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS45
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT44
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS44
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY41
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS40
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES40
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury39
Predicting chimeric antigen receptor apheresis process volume35
“Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits”34
EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS34
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy33
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity33
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba33
Table of Contents32
Editorial Board31
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients30
The Impact of Prior Immunotherapy on Composition of Apheresis Material for CAR T-cell Therapy in Patients with B-Cell Acute Lymphocytic Leukemia (B-ALL)29
MOUSE MESENCHYMAL STROMAL CELL POTENCY ASSAY IN CONTEXT OF USE IN ACUTE LUNG INJURY27
Scalable Production of Hematopoietic Stem Cells and Microglia from iPSCs Using Stirred Tank Bioreactors for Consistent Cell Therapy Manufacturing26
Improving single cell multiomic analysis of T and B cells with innovations enhancing cost-effectiveness and data quality26
Enhancing Gene Transfer Efficiency in Viral and Non-Viral Vectors for Therapeutic Delivery26
An innovative iPSC Reprogramming mRNA-LNP Kit for PBMC26
The hyper-inflammatory ARDS microenvironment enhances MSC reparative capacity in a pre-clinical model of acute lung inflammation25
Classification of Foreign Materials Found in Mesenchymal Stem/Stromal Cell Product Manufacturing25
Streamlined Production of Tumor-Associated Antigen-Specific T Cells (TAAT) from Antigen-Naïve Donors in a GREX Device Using Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same 24
CUTTING-EDGE LIPID-BASED MICROBUBBLE PLATFORM: ENHANCING CELL SORTING24
Thymic Regulatory NK Cells: A Therapeutic Target for Restoring Immune Balance in Chronic Graft-Versus-Host Disease (cGVHD).24
A Narrative Review of Islamic Bioethics and Regenerative Medicine: The Case of Amniotic Fluid Mesenchymal Stem Cells24
Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media24
ACOUSTIC BEADS: A NOVEL METHOD FOR CELL SORTING USING ACOUSTOPHORESIS24
HYDROGEL MICROPARTICLE-BASED ARTIFICIAL ANTIGEN-PRESENTING CELL FOR EFFICIENT EXPANSION AND REACTIVATION OF NK CELLS EX VIVO.23
Initial Experience Implementing a Structured Review Service for Non-GLP Study Data Intended to Support Regulatory Submissions at an Academic Institution23
Elevating MSC-EV Analysis: Development and Qualification of a CD73 Bioactivity Assay23
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN23
Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION23
Hematopoietic Stem/Progenitor Cells and Engineering: HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC23
Mesenchymal Stem/Stromal Cells: TARGETING ENDOGENOUS MESENCHYMAL STROMAL CELL RESPONSE TO INTERFERONγ IN SJÖGREN’S22
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO22
Immunotherapy: EXPANSION AND PROCESSING OF A CLINICALLY RELEVANT NUMBER OF NK CELLS22
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY21
Exosomes/EVs: REAL-TIME BIOPROCESS MONITORING FOR LARGE-SCALE PRODUCTION OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES21
A Simple Approach to Monitor the Cryostorage of Hematopoietic Stem Cells21
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION21
Immunotherapy: TARGETING EWING SARCOMA (ES), OSTEOSARCOMA (OS) AND NEUROBLASTOMA (NB) WITH ANTI-MCAM CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED NATURAL KILLER (NK) CELLS21
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT21
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA21
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the autologous approach from a clin20
Mesenchymal Stem/Stromal Cells: HUMAN MSCS REDUCE INFLAMMATION AND PROMOTE REPAIR IN SEVERE HOUSE DIST MITE INDUCED ALLERGIC AIRWAY DISEASE DRIVEN BY MACROPHAGE MIGRATION INHIBITORY FACTOR20
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING20
Mesenchymal Stem/Stromal Cells: ICE RECRYSTALLIZATION INHIBITOR INCREASES POST-THAW FUNCTIONAL CAPACITY OF BONE MARROW AND UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS20
Mesenchymal Stem/Stromal Cells: HYPERINFLAMMATION AND IMMUNE CELL DYSREGULATION IN C7 HYPOMORPHIC MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: IMMUNE AND INFLAMMATION MODULATION BY HUMAN20
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS20
Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES19
Mesenchymal Stem/Stromal Cells: SUBCUTANEOUS DELIVERY OF ALLOGENEIC INTERFERON-γ LICENSED BONE MARROW DERIVED MESENCHYMAL STROMAL CELL (IFN-γ MSC) FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI)19
PREPARATION OF MUSCLE-DERIVED STEM CELLS SPHEROIDS IN A SCAFFOLD-FREE MICROMOLDED HYDROGEL MAINTAINING THEIR MYOGENIC POTENTIAL19
Aims and Scope19
Exosomes/EVs: Late Breaking Abstract: EFFECTS OF AMNIOTIC FLUID DERIVED EXTRACELLULAR VESICLE BIOLOGIC ON T CELL PROLIFERATION AND ACTIVATION19
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION19
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES19
Immunotherapy: APPLICATIONS OF IMMUNE PROFILING: QUANTITATIVE PHENOTYPIC ANALYSIS OF ALS PATIENTS RECEIVING MSC THERAPY19
Process Development and Manufacturing: VALIDATION OF THE MANUFACTURING OF AUTOLOGOUS MUC-1 ACTIVATED T CELLS FOR A PHASE I DOSE ESCALATION TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA19
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION19
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION18
Mesenchymal Stem/Stromal Cells: MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS HAVE PRESERVED CLONOGENICITY, IMMUNOPOTENCY AND IN VITRO ANTIFIBROTIC EFFECTS18
Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES18
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS18
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?18
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS18
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES18
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY17
Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients17
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO17
Welcome to ISCT 202317
Editorial Board17
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL17
Mesenchymal Stem/Stromal Cells: CELL CULTURE MEDIA (CCM) AND/OR LICENSING SIGNIFICANTLY AFFECTS THE GENE EXPRESSION, SECRETOME AND IMMUNE CELL INTERACTION CAPACITY OF UMBILICAL CORD DERIVED MESENCHYMA17
Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: a controlled randomized phase 1/2 clinical trial16
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA16
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE16
Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation16
Chimeric synthetic T cell receptor and antigen receptor receptors enable high-sensitivity T cell receptor-negative CD8αβ-CD3-positive T-cell development from human-induced pluripotent stem cells15
FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS15
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA15
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up15
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments15
Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products15
A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications15
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway14
A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”14
Therapeutic Potential of First-Trimester Human Umbilical Cord Perivascular Cells in Mitigating Age-Related Muscle Dysfunction in a Natural Mouse Model of Aging14
Advancing Wound Healing with Pre-Activated Umbilical Cord Mesenchymal Stem Cell Secretome14
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions14
Programmed spontaneously beating cardiomyocytes in regenerative cardiology14
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase14
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of 14
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone 14
Secretome of bone marrow mesenchymal stromal cells cultured in a dynamic system induces neuroprotection and modulates microglial responsiveness in an α-synuclein overexpression rat model14
EXPLORING INNOVATIVE BIOREACTOR SYSTEM FOR END-TO-END T CELL MANUFACTURING13
Particulate Management in Bioprocessing: Challenges, Strategies, and Solutions13
Investigating MSC immune suppressive function with quantitative phase microscopy and single-cell spatial lipidomics13
LONG-TERM TOLERANCE TO LEYDIG CELL TRANSPLANTATION WITH LOCALIZED TREG IMMUNOMODULATION USING THE NANOLYMPH PLATFORM13
Key Strategies for Successful Equipment Qualification in Cell Therapy GMP13
A Multi-Donor Characterization of Degradable Microscaffolds for Therapeutic T Cell Manufacturing13
Advancing CAR-NK Cell Engineering by Overcoming Transduction Challenges13
Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction12
Detection of very small embryonic-like stem cells (VSELs) in the peripheral blood of rabbits subjected to induced retinal vein occlusion as a proposed early detection tool for the disease12
Scientific venturing for early-stage professionals (ESPs), a key concept in the innovation ecosystem12
ENEPC-CLI-01- A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED STUDY FOR AUTOLOGOUS BGC-101, ENRICHED ENDOTHELIAL PROGENITOR CELLS, FOR CRITICAL LIMB THREATENING ISCHEMIA12
AdoShell®, a non-fibrotic encapsulation system for cell delivery12
AUTOANTIGEN-SPECIFIC REGULATORY T CELLS HALT THE PROGRESSION OF LUPUS NEPHRITIS12
IMPROVED UNDERSTANDING OF CELL FATE USING A KIDNEY NORMOTHERMIC MACHINE PERFUSION MODEL12
CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities12
Accelerating sterility testing: Symcel calScreener+ achieves results in <3 days with direct inoculation in non-destructive and continuous monitoring system12
BACK TO BASICS: A SCIENTIFIC AND ECONOMIC EVALUATION OF ADHERENT AND SUSPENSION PROCESSING FOR AAV AT SCALE11
BIOMATERIAL-ENABLED MACROPHAGE CELL THERAPY VIA DEXAMETHASONE-LOADED MICROPARTICLES FOR REGENERATIVE MEDICINE11
A NEW ERA OF BIOLOGICS: THE ROLE OF SOUTH KOREA's REGULATORY SCIENCE CENTER IN ENSURING LONG TERM SAFETY11
ABSOLUTE QUANTIFICATION OF GENOMIC TARGETS FOR CELL COUNTING USING DROPLET DIGITAL PCR11
THE MULTI POTENTIALS OF PLACENTA CHORIODECIDUAL MEMBRANES-DERIVED-MSCS (PCMSCS) FOR DECIDUALIZATION AND ANGIO-MYOGENESIS11
NON-VIRAL GENOME EDITING IN HEMATOPOIETIC STEM CELLS (HSCS) FOR CELL-THERAPY APPLICATIONS - FROM DISCOVERY TO MANUFACTURING11
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial11
IMPLEMENTING CUSTOM PARTICLE SWARM-DIFFERENTIAL EVOLUTION OPTIMIZATION (PSODE) FOR GFP PLASMID DNA TRANSFECTION IN JURKAT AND PRIMARY T CELLS11
INSIGHTS INTO SPATIOTEMPORAL DYNAMICS OF ALLOREACTIVE T CELL RESPONSE WITH γMSCS ADMINISTRATION11
IMMUNOMODULATORY POTENTIAL OF ENHANCED MSC-DERIVED EXTRACELLULAR VESICLES11
MANUFACTURE OF A BANK OF “OFF-THE-SHELF” CD30.CAR-EBVSTS FOR THE TREATMENT OF LYMPHOMA11
MESENCHYMAL STROMAL CELLS EXPRESSING DEGRON-HPV16 E5 AS A NOVEL CERVICAL CANCER VACCINE10
Mesenchymal Stem/Stromal Cells: PATIENT RESPONSES TO MESENCHYMAL STROMAL CELL (MSC) THERAPY IN OSTEOARTHRITIS ARE ASSOCIATED WITH DIFFERENTIAL CLINICAL PHENOTYPES, MOLECULAR ENDOTYPES, AND MSC CRITICA10
Mesenchymal Stem/Stromal Cells: UPFRONT USE OF ALLOGENEIC CYTO-MSC IMPROVES RESPONSE AND SURVIVAL RATES IN PATIENTS WITH ACUTE GVHD: AN INTERIM ANALYSIS OF ONGOING PHASE I/II MULTICENTER CLINICAL STUD10
Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies10
Mesenchymal Stem/Stromal Cells: THE INTERFERON-GAMMA-INDOLEAMINE 2,3-DIOXYGENASE 1 (IFN-G-IDO1) AXIS IS NOT INVOLVED IN THE MSC-MEDIATED IMMUNOSUPPRESSION OF ACTIVATED T CELL PROLIFERATION10
Mesenchymal Stem/Stromal Cells: SUSPENSION CULTURE OF HUMAN MESENCHYMAL STROMAL CELLS ON DISSOLVABLE MICROCARRIERS IN AN ANIMAL COMPONENT FREE CULTURE SYSTEM10
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases10
BIOPOTENCY AND SURROGATE ASSAYS TO VALIDATE IMMUNOMODULATORY POTENCY OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM/STROMAL CELLS10
Mesenchymal Stem/Stromal Cells: EVALUATION OF THE EFFECT OF MEDIUM COMPOSITION ON THE PHENOTYPIC AND FUNCTIONAL ATTRIBUTES OF MESENCHYMAL STROMAL CELLS10
Mesenchymal stromal cells regulate THP-1–differentiated macrophage cytokine production by activating Akt/mammalian target of rapamycin complex 1 pathway10
Process Development and Manufacturing: SUPERIOR EXPANSION OF γδ T-CELL SUBSETS FOR SOLID TUMOR T-CELL THERAPY USING A CHEMICALLY-DEFINED NON-ANIMAL ORIGIN SERUM-FREE CULTURE MEDIUM10
Subscription information10
Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL10
The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients10
MULTIOMIC PROFILING OF EX VIVO EXPANDED CD45 (+)CD34(BRIGHT) CD38(-) CD90(+) CD49F(+)CELLS REVEALS NOVEL PATHWAYS FOR THE LONG-TERM MAINTENANCE OF HEMATOPOIETIC STEM AND PROGENITOR CELLS10
Gene Editing/Gene Therapies: GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATED VIA HER2 AND TRAIL10
2023 Gene Therapy Mini-Series10
Immunotherapy: PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION10
Regulatory Affairs, Quality Systems, Policy, and Ethics: EVALUATION OF PERCENTAGE CHANGE IN PRE-DONATION AND POST-DONATION LABORATORY VALUES AFTER REPEATED (MNC), APHERESIS DONATIONS10
Immunotherapy: ANTI-GD2 CAR T CELLS AGAINST SMALL CELL LUNG CANCER10
Mesenchymal Stem/Stromal Cells: MSC AND THEIR ISOLATED MITOCHONDRIA IMPROVE THE REGENERATION OF MICE CUTANEOUS SURGICAL WOUNDS BY IN-SITU INJECTION9
Mesenchymal Stem/Stromal Cells: EFFECTS OF COLD STORAGE ON MITOCHONDRIAL BIOENERGETICS AND PROTEIN IN HUMANMSCS9
iPSC: THE IPS DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE9
Mesenchymal Stem/Stromal Cells: SINGLE-CELL TRANSCRIPTOMICS COMPARISON OF CELL THERAPEUTICS IN OSTEOARTHRITIS9
Immunotherapy: ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE9
Immunotherapy: CONVERTING IMMUNOLOGICALLY “COLD” MICROSATELLITE-STABLE COLORECTAL CANCER TO “HOT” BY DNA METHYLTRANSFERASE INHIBITOR AND RADIATION TO ENHANCE THERAPEUTIC EFFICACY9
Immunotherapy: ALLOCETRA-OTS, AN EARLY APOPTOTIC CELLULAR THERAPY SYNERGIZE WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY OR IMMUNE CHECK POINT INHIBITOR AGAINST PERITONEAL SOLID TUMOR9
Process Development and Manufacturing: HIGH DENSITY BATCH CULTURES OF WJ-HMSCS IN STIRRED-TANK BIOREACTORS EQUIPPED WITH THE NOVEL BACH IMPELLER9
Mesenchymal Stem/Stromal Cells: CELL CERAMTM ASSOCIATED WITH HUMAN LEVATOR VELI PALATINI MUSCLE STROMAL CELLS TO BONE RECONSTRUCTION IN CRANIOFACIAL SYNDROMES9
Subscription information9
The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy9
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: GRAPHENE DERIVATES FOR BONE TISSUE REGENERATION9
Regulatory Affairs, Quality Systems, Policy, and Ethics: TESTING CELL THERAPY AND BIOPRODUCTION SAMPLES USING THE BIOFIRE® MYCOPLASMA MOLECULAR LAB IN A POUCH SYSTEM9
Mesenchymal Stem/Stromal Cells: TRANSCRIPTIONAL TARGETS OF TWIST1 IN HUMAN MESENCHYMAL STEM/STROMAL CELLS9
Exosomes/EVs: MSC-DERIVED EVS ATTENUATE ATOPIC DERMATITIS BY SUPPRESSING INFLAMMATION AND PROMOTING EPIDERMAL BARRIER REPAIR9
Gene Editing/Gene Therapies: ENHANCING ANTI-OXIDATION OF MESENCHYMAL STROMAL/STEM CELLS USING CRISPR/CAS9 FOR INFLAMMATORY AND ISCHEMIC-REPERFUSION INJURY9
Author index9
Immunotherapy: THE BTLA-HVEM AXIS IS A CRUCIAL IMMUNE CHECKPOINT OF T CELL IMMUNOTHERAPIES FOR CANCER9
Mesenchymal Stem/Stromal Cells: IND CMC COMPATIBLE PURITY AND IDENTITY ASSESSMENT OF IFNγ-STIMULATED BONE MARROW SOURCED MESENCHYMAL STROMAL CELLS FOR A PHASE I CLINICAL TRIAL9
Mesenchymal Stem/Stromal Cells: INTRAVENOUS INJECTION OF XENOGENEIC MITOCHONDRIA ISOLATED FROM HUMAN FIBROBLAST AND MESENCHYMAL STEM/ STROMAL CELLS (MSC) ARE DETECTED IN THE HEART, INDUCE PGC-1α AND I9
IMMUNOMODULATORY POTENTIAL OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM CELLS OBTAINED BY ULTRAFILTRATION AND ULTRACENTRIFUGATION9
Advanced therapies require soft skills: insights from a National Academies Working Group8
PRE-CLINICAL CHARACTERIZATION OF ALLOCETRATM; A NOVEL MACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA-ARTICULAR TREATMENT IN OSTEOARTHRITIS8
Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies8
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia8
Increasing access to transplantation through telemedicine and patient navigation8
PROCESS DEVELOPMENT FOR SCALABLE ALLOGENEIC CAR-T MANUFACTURING IN STIRRED-TANK BIOREACTORS: PERFUSION OPTIMISATION, MULTI-LITRE SCALE-UP AND AUTOMATED HARVESTING8
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee8
The emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials8
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances8
Tissue Engineering: DEVELOPMENT OF A TISSUE-ENGINEERED PRODUCT FOR GINGIVAL RECESSION8
Gene Editing/Gene Therapies: EVALUATION OF TRANSFECTION REAGENTS FOR HIGH TITER LENTIVIRUS PRODUCTION IN THE ICELLIS NANO BIOREACTOR8
The imperative to investigate epigenetic and transcriptional fidelity in long-term cryopreserved hematopoietic stem and progenitor cells8
Real World Experience of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program: primary referral to TIL infusion (Brain to Vein)8
Dual-CAR NK cells targeting PD-L1 and ErbB2/HER2 eliminate solid tumor cells and prevent immune escape due to antigen loss8
THE ASSESSMENT OF WOMEN'S EDUCATION IN MEXICO ON CORD BLOOD (CB) BANKING AND ETHICAL IMPLICATIONS8
Challenging immunophenotyping of patients with sickle cell disease adversely affects gene therapy product manufacturing – case reports.8
Outcomes following hematopoietic cell transplantation for children, adolescents and young adults with relapsed acute lymphoblastic leukemia8
Gene Editing/Gene Therapies: A NOVEL WEIGHT-BASED APPROACH TO DETERMINE CELL TYPE SPECIFICITY FROM SINGLE CELL DATASETS8
Yeast Surface Display Meets Immunotherapy: Unlocking the Potential of T Cells8
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort8
INVESTIGATING THE ADVANCEMENTS IN MESENCHYMAL STEM CELLS AND THEIR SECRETOME: UNVEILING THE POTENTIAL FOR FACIAL REJUVENATION7
Mesenchymal Stem/Stromal Cells: HIGH-DIMENSIONALL MULTI-OMICS COMPARISON OF CELLS IN BONE MARROW REVEALED ALTERATIONS TO IMMUNE CELLS IN OSTEOARTHRITIS7
Immunotherapy: SIGNALING DOMAINS, 41BB AND CD28, MEDIATE DISTINCT MOLECULAR DYNAMICS AT THE IMMUNE SYNAPSE THAT INFLUENCE CAR T CELL KILLING BEHAVIOR7
Process Development and Manufacturing: OPTIMIZATION OF CHONDRON RECOVERY PROCEDURE FROM AUTOLOGOUS CARTILAGE OF THE FEMOROACETABULAR JOINT7
VIABILITY, DIFFERENTIATION PROFILE AND GENIC EXPRESSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS CULTURED ON PLA/COL/HA/MSC-WJ CONSTRUCTS AS AN EX VIVO EXPANSION STRATEGY7
Immunotherapy: NK CELL EXPANSION USING SCALE UP BIOREACTORS FOR CELL THERAPY7
Immunotherapy: OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY: A NEW POSSIBILITY FOR COVID- 19 TREATMENT7
A machine-learning model that incorporates CD45 surface expression predicts hematopoietic progenitor cell recovery after freeze–thaw7
COMPARATIVE CHARACTERIZATION OF HUMAN DERMAL MESENCHYMAL STROMAL CELLS FROM DIFFERENT ANATOMICAL LOCATIONS AND ACROSS THE LIFESPAN7
EFFECTS OF IGF-1-OVEREXPRESSING MESENCHYMAL STROMAL CELL TRANSPLANTATION IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS7
A PLATFORM FOR THE ISOLATION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES - EXPLORING A COMPREHENSIVE COLLECTION OF HUMAN EV7
Tissue Engineering: AUTOFLUORESCENCE IMAGING IDENTIFIES KEY SUBSTRATE PROPERTIES TO SUPPORT STEM CELL-DERIVED CARDIOMYOCYTE DIFFERENTIATION7
Exosomes/EVs: Late Breaking Abstract: MSC-DERIVED EXTRACELLULAR VESICLES WITH ANTI-VIRAL EFFICACY ALLEVIATE VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME7
Hematopoietic Stem/Progenitor Cells and Engineering: A NEW METHOD FOR THE AUTOMATED ENUMERATION AND ANALYSIS OF CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS BY FLOW CYTOMETRY7
Immunotherapy: IMPROVING CAR T CELL EFFICACY IN A PRECLINICAL MODEL OF BREAST CANCER THROUGH MODIFIED MANUFACTURING METHODS AND ADJUVANT THERAPY7
Process Development and Manufacturing: EFFECT OF DONOR AND METHOD VARIABILITY ON BIOMANUFACTURING PROCESS ESTABLISHMENT7
Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice7
Mesenchymal Stem/Stromal Cells: ROLE OF REACTIVE OXYGEN SPECIES IN SUPPRESSION OF ALLOREACTIVE T-CELLS BY INTERFERON-GAMMA PRIMED-MESENCHYMAL STROMAL CELLS7
Aims and Scope7
Integrating cell confinement in a perfusion bioreactor improves iMSC extracellular vesicle production and potency7
MULTIOMIC ANALYSIS OF γMSC-SUPPRESSED ALLOREACTIVE T CELLS7
Exosomes/EVs: GROWTH MEDIA CONDITIONS INFLUENCE THE SECRETION ROUTE AND RELEASE LEVELS OF ENGINEERED EXTRACELLULAR VESICLES7
Process Development and Manufacturing: CHALLENGES AND SOLUTION FOR PERFORMANCE VALIDATION OF EM AUTOMATION7
Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GE7
CHARACTERIZATION AND EVALUATION OF GENETIC STABILITY OF URINE-DERIVED STEM CELLS7
Mesenchymal Stem/Stromal Cells: TRANSCRIPTOMIC ANALYSIS OF HUMAN MESENCHYMAL STEM CELLS FROM UMBILICAL CORD EXPANDED WITH INACTIVATED GMP-GRADE HUMAN PLATELET LYSATE7
Mesenchymal Stem/Stromal Cells: COMPARISON ON THE CURATIVE EFFECTS OF MESENCHYMAL STEM CELL TRANSPLANTATION AND LOW-DOSE INTERLEUKIN-2 TREATMENT ON SYSTEMIC LUPUS ERYTHEMATOSUS7
Process Development and Manufacturing: C3P3-G3 ARTIFICIAL EXPRESSION SYSTEM FOR HIGH PERFORMANCE LENTIVIRUS PRODUCTION WITH IMPROVED PREDICTED BIOSAFETY7
Exosomes/EVs: ADIPOSE-DERIVED STEM CELL SECRETOME TRIGGERS TGFβ-PSMAD SIGNALING IN CHONDROCYTES AND IS A PROMISING THERAPY FOR OSTEOARTHRITIS MODEL7
Label-free, single-cell quantification of granulocyte macrophage progenitors from brightfield imaging7
STERILITY SAMPLING OF CELL, GENE, AND TISSUE THERAPY PRODUCTS (ATMPs)7
ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS7
MICROFLUIDICS IMPROVES LENTIVIRUS TRANSDUCTION EFFICIENCY7
EVALUATION OF IN VIVO TOXICITY OF CLINICAL-GRADE EXTRACELLULAR VESICLES DERIVED FROM HUMAN MESENCHYMAL STROMAL CELLS6
Editorial Board6
G-CSF-primed Allogenic Bone Marrow-derived Mesenchymal Stem Cells Induce Suppression of Clonal Proliferation of BCR/ABL positive Chronic Myeloid Leukmemia6
The dual role of PPARβ/δ nuclear receptor in MSC immunomodulatory and pro-reparative capacity in a model of acute lung inflammation6
THE TETRAVECTA™ SYSTEM: A NEW TOOL KIT ENHANCING LENTIVIRAL VECTOR PRODUCTION FOR THE NEXT GENERATION OF GENE THERAPIES6
Immunomodulatory Effects of Human Dental Pulp Stem Cells on Monocyte Polarization via Efferocytosis6
Mesenchymal Stem/Stromal Cells: CARTILAGE REPAIR BY HUMAN PLACENTA-DERIVED MESENCHYMAL STEM CELLS AND HYALURONIC ACID HYDROGEL IN A MINIPIG MODEL6
Immunotherapy: UTILIZATION OF BIDIRECTIONAL PROMOTERS IN SLEEPING BEAUTY-BASED DUAL CHIMERIC ANTIGEN RECEPTOR T CELL6
CHARACTERIZATION OF CANINE UMBILICAL CORD MESENCHYMAL STEM CELLS6
Mesenchymal Stem/Stromal Cells: EXTRACTS FROM CHLORELLA VULGARIS PROTECT MESENCHYMAL STROMAL CELLS FROM OXIDATIVE STRESS INDUCED BY HYDROGEN PEROXIDE6
Gene Editing/Gene Therapies: MOVING THE NEEDLE FOR CELL THERAPIES: A NEXT-GENERATION EX VIVO PLATFORM USING NANONEEDLES FOR PRECISION CARGO DELIVERY6
From Bench to Bedside – ongoing Clinical Development in Organoids and cell Therapy in Europe6
Comparative Analysis of Total Antibody Titer and Neutralizing Antibody Titer: Correlation and Implications for AAV-Based Gene Therapies.6
THE AMETHYST (ADVANCED MESENCHYMAL ENHANCED CELL THERAPY FOR SEPTIC) TRIAL: A FIRST-IN-HUMAN, DOSE-ESCALATION PHASE 1 SAFETY TRIAL OF GENETICALLY ENHANCED MSCS (GEM00220) APPEARED SAFE AND WELL TOLERA6
Mesenchymal Stem/Stromal Cells: CHEMICALLY DEFINED BIOMATRICES FOR MSC MANUFACTURING – FROM ISOLATION TO MICROCARRIER-BASED EXPANSION6
Mesenchymal Stem/Stromal Cells: THE IMPORTANCE OF CHEMICALLY-DEFINED MEDIA IN HAIR FOLLICLE CELL CULTURE FOR HAIR LOSS CELL THERAPY6
Living medicines: Training before handling6
Gene Editing/Gene Therapies: EFFICIENT AND GENTLE NON-VIRAL ENGINEERING OF CELLS IN VITRO AND EX VIVO BY PHOTOPORATION6
Regulatory Considerations for the Review System of Unproven Stem Cell Therapies in Japan6
ENHANCING HUMAN MESENCHYMAL STEM CELL MICROCARRIER CULTURE THROUGH PERFUSION PROCESS DEVELOPMENT6
Quantitative Predictive Cellular Analytics Driving Improvements in Advanced Therapy Development and Manufacturing6
Exosomes/EVs: MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES: A NEW TREATMENT PARADIGM FOR SOLD ABDOMINAL ORGAN TRANSPLANT PATIENTS WTIH ALLOGRAFT FAILURE AND GRAFT VERSUS HOST DISEASE6
Process Development and Manufacturing: ESTABLISHING CELL VIABILITY MEASUREMENTS THAT PREDICT PROLIFERATIVE CAPACITY IN A MODEL SYSTEM6
Embryonic, Organ and Other Tissue Specific Stem Cells: INFLAMMATORY CYTOKINE EFFECTS ON HEPATIC METABOLISM IN PRIMARY HUMAN HEPATOCYTES: A REVISED EVALUATION OF DONOR CELL FATE AFTER TRANSPLANTATION6
Regulatory Affairs, Quality Systems, Policy, and Ethics: VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ ALERT® 3D™ AND VIRTUO™ SYSTEMS FOR HAEMA6
0.30603504180908